Replies to post #235449 on Biotech Values

[DewDiligence]

ASMB/ENTA/etc—I respectfully disagree with a tweep (and some people here on iHub) about the relevance of HBsAg:

Respectfully disagree. $ASMB genuinely thinks HBsAg is an overrated marker, and they might end up being right about this.

— Roy Friedman (@DewDiligence) November 6, 2020

I.e., I don’t think ASMB has been cynically downplaying HBsAg because ABI-H0731 had little effect on HBsAg, but rather because ASMB’s scientists sincerely believe that HBsAg is the wrong biomarker to focus on.

[DewDiligence]

ASMB -66%—much worse than -37% in yesterday’s AH session.

[DewDiligence]

ASMB seems to be acknowledging that its in-house CpAMs are not good enough:

https://www.globenewswire.com/news-release/2020/11/16/2127221/0/en/Assembly-Biosciences-and-Door-Pharmaceuticals-Sign-Collaboration-and-Option-Agreement-to-Develop-a-Novel-Class-of-HBV-Core-Protein-Modulators.html